Correlation of Base-Line Trough Tacrolimus Level With Early Rejection

Manish Tripathi*

Live donor renal transplantation, Ajman, United Arab Emirates

***Corresponding author:** Manish Tripathi, Live donor renal transplantation, Ajman, United Arab Emirates

Submission: October 26, 2017; **Published:** January 17, 2018

Aim and Objective of the study

To analyze the co-relation of baseline trough (C₀) tacrolimus level, with early rejection in living donor transplants.

Materials and Methods

Study area

The study was done at Muljibhai Patel Urological Hospital, Nadiad, Gujarat. It is a tertiary health care centre, for nephrology, with a well established hemodialysis unit. We have done about 1950 renal transplantation so far. Acute rejection is the most significant risk factor for chronic rejection and potential surrogate for long-term graft failure. Aim of our study was to analyze the association between the baseline through (C₀) tacrolimus level in the first day post transplant, with early rejection in living donor transplants [1-10].

Study population

All patients enrolled were older than 18 years. The protocol received approval from the Ethical Committee of Muljibhai Patel Urological Hospital Society. All the patients in the study received pre-transplant immunosuppression starting 3 days prior to transplant. The follow up period was 1 year post- transplant [11-20].

Sample size and sample technique

179 patients were evaluated. This was an open label randomized prospective study consisting of renal allograft recipients from living donors. This study was carried out by Department of Nephrology at Muljibhai Patel Urological Hospital, Nadiad, between January 2008 to September 2009 [21-30].

Data collection technique and tools

Demographic, baseline characteristics and outcome characteristics were collected throughout the first year post-transplant. Demographic data included donor and recipient age, gender, relation and underlying native kidney disease. Baseline transplant information included induction used, anti-proliferative used, number of HLA mismatches, graft renal artery number(single or dual), WIT and CIT. Data on complications was also collected

including post transplant rejections, surgical complications, infections, liver dysfunctions, PTDM, TAC nephrotoxicity, and delayed graft functions (DGF). DGF was defined as need for dialysis in the first week post-transplant. PTDM was defined as requirement for oral hypoglycemic agents or insulin for the first time post-transplant. The outcome was assessed on the incidence and severity of acute rejection in correlation to base-line trough tacrolimus level measured on day 0 of transplantation. The side-effects of the immunosuppressive therapy was also assessed in the form of; episodes of post-transplant infection and their severity; liver dysfunction; PTDM and its severity (transient or persistent; requiring OHAs or insulin) [31-40].

Patients were divided and analyzed in three groups based on base-line trough TAC level on day 0 post-transplant: Group 1: TAC 0-5ng/ml (n=34), Group 2 : TAC 5-15ng/ml (n=112), Group 3: TAC>15ng/ml (n=33).

Data Analysis

Simple statistical tools were used for calculating demographic parameters. The difference between the two group means was tested using Student's t-test and the presence of episode within two groups by 2x2 Chi-square test. SPSS version 15.0 was used to carry the logistic regression analysis and to find the Pearson's correlation coefficients [41-50].

Salient Findings (Table 1-6)

Table 1: Comparison of the baseline demographic features between the 3 groups.

	<5 (n=34)	05-15 (n=112)	>15 (n=33)
Age	49.06+10.15	47.38+9.6	46.42+10.2
Gender (M:F)	24:10	94:18	27:6
Relation Related	28	76	22
Other than related	06	36	11
Donor Age	49.05+10.15	47.7+10.14	46.42+10.2
Donor Gender	9:25	39:73	13:20
Total Ischemia Time	61.32+17.58	57.15+9.7	58.42+13.61

Table 2: Various degree of HLA mismatch in all 3 groups.

	<5 (n=34)	05-15 (n=112)	>15 (n=33)
1	06	17	03
2	15	38	14
3 (haplo)	09	27	08
4	02	07	01
5	01	03	01
6 (nil)	00	05	01

Table 3: Immunosuppression protocols used and their related toxicity in the 3 groups.

	<5 (n=34)	05-15 (n=112)	>15 (n=33)
Induction	15	35	17
Anti proliferative -Azathioprine	20	50	11
Anti proliferative - MMF	14	62	22
Biopsy proven CNI toxicity	2(5.9)	9(8.03)	5(15.1)
NOD	17(50)	42(37.5)	14(42.4)

Table 4: Non-infectious complications occurring during hospitalization and outpatient follow-up.

Non-Infectious Complications	<05	05-15	>15	Total case (n=10)
Femoral neuropathy	01	-	01	02
GI side effects of MMF	-	-	03	03
Hypertensive encephalopathy	-	01	-	01
Proteinuria	-	-	01	01
TMA	-	01	-	01
TRAS	-	02	-	02

Table 5: Infectious complications.

Post transplant Infections	<05	05-15	>15	Total case (n=57)
AGE	01	04	-	5
CMV	02	08	04	14
FUNGAL	01	-	-	1
LRTI	01	01	01	3
TB	01	01	-	2
UTI	05	11	07	26
HBV	-	02	01	3
HCV	-	-	01	1
Lymphocoeel	-	01	-	1
VZ-1	-	01	-	1
PV-1	-	01	-	1

Table 6: Number of rejection in each group, their Banff grading and outcomes.

	<5 (n=34)	05-15(n=112)	>15(n=33)
Rejection Episodes	12 (35.3)	27(24.1)	5(15.2)
TCMR 1A	3	10	2
TCMR 1B	3	3	0
TCMR 2A	2	4	0
AMR 1	1	3	0
AMR 3	0	1	0
Graft loss	0	2	0
Post Tx Infections	12 (35.3)	33(29.5)	15(45.4)

Our study showed a significant reduction in the incidence of early rejection as the baseline (pre-transplant) trough tacrolimus level increases. Patients in Group 3 had significantly lower rate of biopsy proven rejections than Group 1 ($p=0.001$). It also shows that with higher trough level severity of rejection also reduces and that there was no severe TIR and antibody mediated rejection when trough level was $>15\text{ng/ml}$ [51-60].

Our study also showed that the incidence of NODAT was not different among various trough levels; although there was a trend towards higher rate of biopsy proven nephrotoxicity with higher trough levels. It was also seen that only 18% of the patients could achieve a baseline trough level of $>15\text{ng/ml}$ in spite of being started on same doses of tacrolimus (0.15mg/kg) pretransplant. This shows a wide variability in tacrolimus handling in humans [61-75].

Conclusion

- Incidences of early rejection reduces as the pretransplant trough tacrolimus level increases [71]
- With higher trough level severity of rejection also reduces and we did not encounter any severe TIR or antibody mediated rejection when trough level was $>15\text{ng/ml}$ [72]
- NOD was not different among various trough levels and trend towards higher nephrotoxicity with higher trough levels [73]
- Only 18 % could achieve the trough level of $>15\text{ng/ml}$ [74,75]

Recommendation

Our results suggest that targeting baseline (pretransplant) trough (T0) tacrolimus levels similar to those seen in Group 3 ($>15\text{ng/ml}$) immediately post-transplant can yield extremely low ACR rates in the long term. Thus, we propose that a target baseline trough tacrolimus levels similar to that seen in Group 3 would achieve the optimal balance between efficacy and toxicity.

References

- Arrazola L, Sozen H, Humar A, Papalois V, Uknis M, et al. (2000) Both immunologic and nonimmunologic factors are risks for long-term graft survival - a multivariate analysis. Transplant Proc 32(7): 1831.

2. Humar A, Ramcharan T, Kandaswamy R, Gillingham K, Payne WD, et al. (2002) Risk factors for slow graft function after kidney transplants: a multivariate analysis. *Clin Transplant* 16(6): 425-429.
3. Paraskevas S, Kandaswamy R, Humar A, Gillingham K, Gruessner RW, et al. (2003) Predicting long-term kidney graft survival: can new trials be performed? *Transplantation* 75(8): 1256-1259.
4. Suthanthiran M, Strom TB (1994) Renal transplantation. *N Engl J Med* 331(6): 365-376.
5. Magee CC, Denton MD, Mieford EL. (1999) Immunosuppressive agents in organ transplantation. *Hosp Med* 1999;60: 364.
6. <http://www.centerspan.org>.
7. Lindholm A, Ohlman S, Albrechtsen D, Tufvesson G, Persson H, et al. (1993) The impact of acute rejection episodes on long term graft function and outcome in 1337 primary renal transplants treated by 3 cyclosporin regimens. *Transplantation* 56: 307-315.
8. Matas AJ, Gillingham KJ, Payne WD, Najarian JS (1994) The impact of an acute rejection episode on long-term renal allograft survival. *Transplantation* 57(6): 857-859.
9. Takahara S, Kokado Y, Kameoka H, Takano Y, Moutabarrik et al. (1994) A Monitoring of FK506 blood levels in kidney transplant recipients. *Transplantation Proc* 26(4): 2106-2108.
10. Kerhner R, Fitsimmons WE (1996) Relationship of FK 506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. *Transplantation* 62(7): 920-926.
11. Winker M, Wonigeit K, Undre N (1995) Comparison of plasma vs whole blood as matrix for FK506 drug level monitoring. *Transplantation Proc* 27: 822-825.
12. Undre NA, van Hooff J, Christianns M, Vanrenterghem Y, Donck J, et al. (1999) Low systemic exposure to Tacrolimus correlates with acute rejection. *Transplant Proc* 31(1-2): 296-298.
13. Backman L, Levy MF (1995) Klintmalm and the FK506 Multicentre Study Group. Whole-blood and the plasma levels of FK506 after liver transplantation: Results from the US Multicenter Trial. *Transplant Proc* 27: 1124.
14. Backman L, Nicar M, Levy M, Distant D, Eisenstein C, et al. (1994) FK506 trough levels in whole blood and plasma in the liver transplant recipients. *Transplantation* 57(4): 519-525.
15. Jain AB, Todo S, Fung JJ, R Venkataramanan, R Day, et al. (1991) Correlation of rejection episodes with FK 506 level and the steroids following primary orthotopic liver transplantation. *Transplant Proc* 23(6): 3023-3025.
16. Japanese FK506 Study Group (1991) Japanese study of FK506 on kidney transplantation: The benefit of monitoring the whole blood FK506 concentration. *Transplant Proc* 23: 3023-3025.
17. Bottiger Y, Battstrom C, Tyden G, Sawe J, Groth CG (1999) Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. *Br J Clinical Pharmacology* 48(3): 445-448.
18. Winkler M, Ringe B, Baumann J, Loss M, Wonigiet K, et al. (1994) Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression. *Clin Chem* 40(12): 2247-2253
19. Winkler M, Wonigiet K, Undre N, Ringe B, et al. (1995) Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. *Transplant Proc* 27(1): 822-825.
20. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B et al. (1997) Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. *Transplantation* 64(3): 436-443.
21. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS et al. (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. *FK506 Kidney Transplant Study Group. Transplantation* 63(7): 977-983.
22. Jensik SC (1998) Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. *European Tacrolimus Multicentre Renal Study Group. Transplant Proc* 30(4): 1261-1263.
23. Mayer AD (1999) Four year follow up of European tacrolimus multicenter renal study. *Tr Transplant Proc* 31(7A): 27S-28SC.
24. Johnson, Ahsan N, Gonwa T, Halloran P, Stegall M, et al. (2000) Randomized trial of tacrolimus in combination with azathioprine or mycophenolate mofetil versus cyclosporine with mycophenolate mofetil after cadaveric renal transplant. *Transplantation* 69(5): 834-841.
25. Schweitzer EJ, Matas AJ, Gillingham KJ, et al. (1991) Causes of renal allograft loss: progress in the 1980s, challenges for the 1990s. *Ann Surg* 214(6): 679-688.
26. Massy ZA, Guijarron C, Wiederkehr MR, Ma JZ, Kasiske BL (1996) Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors. *Kidney Int* 49(2): 518-524.
27. Matas ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL (1996) Chronic renal allograft rejection: Immunological and nonimmunological risk factors. *Kidney Int* 49(2): 518-524.
28. Matas AJ, Gillingham KJ, Payne WD, Najarian JS (1994) The impact of acute rejection episode on long-term renal allograft survival(t ½). *Transplantation* 57(6): 857-859.
29. Cosio FG, Pelletier RP, Falkenhain ME, Henry ML, Elkhammas EA, et al. (1997) Impact of acute rejection and early allograft function on renal allograft survival. *Transplantation* 63(11): 1611-1615.
30. Opelz G (1997) for the Collaborative transplant study. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. *Transplant Proc* 29(1-2): 73-76.
31. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA (1992) FK-506-and CsA- sensitive activation of the interleukin-2 promoter by calcineurin. *Nature* 357(6380): 692-694.
32. Clipstone NA, Crabtree GR (1992) Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. *Nature* 357: 695-697.
33. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, et al. (1991) Calcineurin is a common target of cyclophilin-cyclosporin A AND fkbpfk506 complexes. *Cell* 66(4): 807-815.
34. Fruman DA, Klee CB, Bieri BE, Burakoff SJ (1992) Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporine A. *Proc Natl Acad Sci U S A* 89(9): 3686-3690.
35. Schreiber SL (1992) Immunophilin-sensitive protein phosphatase action in cell signaling pathways. *Cell* 70(3): 365-368.
36. Cecka JM, Terasaki PI (1995) The UNOS Scientific Renal Transplant Registry. In: Terasaki PI, Cecka JM, eds, *Clinical transplants 1992*. Los Angeles UCLA Tissue Typing Laboratory 1-18.
37. Terasaki PI, Cecka JM, Gjertson DW, Cho Y, Takemoto S, Cohn M (1993) A ten-year prediction for renal transplant survival. In: Tersaki PI, Cecka JM, eds. *Clinical transplants 1992*. Los Angeles: UCLA Tissue Typing Laboratory pp. 501-512.
38. Basdonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, et al. (1993) Relationship between early and late acute rejection and onset of chronic rejection in kidney transplantation. *Transplant Proc* 25(1-2): 910-911.
39. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, et al. (1993) Risk factors for chronic rejection in renal allograft recipients. *Transplantation* 55(4): 752-756.
40. Basdonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, et al. (1993) Early versus late acute renal allograft rejection: impact on chronic rejection. *Transplantation* 55(5): 993-995.
41. Land W, Schneeberger H, Schleibner S (1991) Long-term results in cadaveric renal transplantation under cyclosporine therapy. *Transplant*

- Proc 23: 1244.
42. Matas A (1994) Chronic rejection in renal transplant recipients: risk factor and correlates. *Clin Transplant* 8(3-2): 332-335.
 43. Vanrenterghem YF (1995) Acute rejection and renal allograft outcome. *Nephrol Dial Transplant* 10(suppl 1): 29-31.
 44. Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, et al. (1993) The impact of acute rejection episodes on long term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporin regimens. *Transplantation* 56(2): 307-315.
 45. Cecka JM, Terasaki PI (1991) The UNOS scientific renal transplant registry, 1990. In: Terasaki PI, Cerka JM (Eds.), *Clinical transplants 1990*. Los Angeles: UCLA Tissue typing laboratory 1991: 1-18.
 46. Cecka JM, Terasaki PI. (1995) The UNOS scientific renal transplant registry. In: Terasaki PI, Cerka JM (Eds.), *Clinical transplants 1994*. Los Angeles: UCLA Tissue Typing Laboratory, p. 1-18.
 47. Japanese FK 506 Study Group (1991) Japanese study of FK 506 on kidney transplantation: results of an early phase 2 study. *Transplant Proc* 23(6): 3071-3074.
 48. Japanese FK (1993) 506 Study Group. Japanese study of FK 506 on kidney transplantation: results of an early phase 2 study. *Transplant Proc* 25: 649.
 49. Japanese FK (1995) 506 Study Group. FK 506: Long term study in kidney transplantation. *Transplant Proc* 27: 818.
 50. Japanese FK 506 (1995) Study Group. Phase 3 study of FK 506 in kidney transplantation. *Transplant Proc* 27: 829.
 51. Schleibner S, Krauss M, Wagner K, Erhard J, Christiaans M, et al. (1995) FK 506 versus cyclosporine in the prevention of renal allograft rejection: European pilot study-six-week results. *Transpl Int* 8(2): 86-90.
 52. Laskow DA, Vincenti F, Neylan J, Mendez R, Matas A (1995) Phase 2 FK 506 multicenter concentration control study: one-year follow up. *Transplant Proc* 27(1): 809-811.
 53. Shapiro R, Jordan M, Scantlebury V, Fung J, Jensen C, et al. (1991) FK 506 in the clinical kidney transplantation. *Transplant Proc* 23(6): 3065-3067.
 54. Shapiro R, Jordan M, Scantlebury V, et al. (1995) A prospective randomized trial of FK 506- based Immunosuppression after renal transplantation. *Transplantation* 344: 423.
 55. Jordan ML, Shapiro R, Vivas CA, Velma P. Scantlebury, Parmjeet Rhandhawa, et al. (1994) FK506 "rescue" for resistant rejections of renal allografts under primary cyclosporine Immunosuppression. *Transplantation* 57(6): 860-865.
 56. Undre NA, Stevenson P, Schafer A (1999) Pharmacokinetics of tacrolimus: clinically relevant aspects. *Transplant Proc* 31(7): 21-24.
 57. Undre NA, van Hooff J, Christiaans M, Vanrenterghem Y, Donck J, (1999) et al. Low systemic exposure to tacrolimus correlates with acute rejection. *Transplant Proc* 31(1-2): 296-298.
 58. Bottiger Y, Undre NA, Sawe J, Stevenson PJ, Ericzon BG (2002) Effect of bile flow on the absorption of tacrolimus in the liver allograft transplantation. *Transplant Proc* 34(5): 1544-1545.
 59. Kershner RP, Fitzsimmons WE (1996) Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. *Transplantation* 62(7): 920-926.
 60. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. *Transplantation* 63(7): 977-983.
 61. Mayer AD, Dmitrewwski J, Squifflet JP, Besse T, Grabensee B, et al. (1997) Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. *Transplantation* 64(3): 436-443.
 62. Morris-Stiff G, Ostrowski K, Balaji V, Moore R, Darby C, et al. (1998) Prospective randomised study comparing tacrolimus (Prograf) and cyclosporin (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: Interim report of the first 80 cases. *Transpl Int* 11(Suppl 1): S334-S336.
 63. Busque S, Shoker A, Landsberg D, McAlister V, Halloran P, et al. (2001) Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation. *Transplant Proc* 33(1-2): 1266-1267.
 64. Margreiter R (2002) Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomized multicentre study. *Lancet* 359(9308): 741-746.
 65. Murphy GJ, Waller JR, Sandford RS, Furness PN, Nicholson ML (2003) Randomized clinical trial of the effect of micro microemulsion cyclosporin and tacrolimus on renal allograft fibrosis. *Br J Surg* 90(6): 680-686.
 66. Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G (2003) A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. *Transplantation* 75(6): 844-851.
 67. Hardinger KL, Bohl DL, Schnitzler MA, Lockwood M, Storch GA, et al. (2005) A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with Thymoglobulin in renal transplant recipients. *Transplantation* 80(1): 41-46.
 68. Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P (2005) Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. *Transplantation* 79(7): 807-814.
 69. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B (2006) Symphony: Comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. *Transplantation* 82: 83.
 70. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL (2001) Cyclosporin: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral)1 in organ transplantation. *Drugs* 61(13): 1957-2016.
 71. Christiaans M, van Duijnhoven E, Beysens T, Undre N, Schafer A, et al. (1998) Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. *Transplant Proc* 30(4): 1271-1273.
 72. Halloran PF, Helms LM, Kung L, Noujaim J (1999) The temporal profile of calcineurin inhibition by cyclosporine in vivo. *Transplantation* 68(9): 1356-1361.
 73. Stein CM, Murray JJ, Wood AJ (1999) Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect. *Clin Chem* 45(9): 1477-1484.
 74. Hartel C, Fricke L, Schumacher N, Kirchner H, Muller-Steinhardt M (2002) Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: A quantitative measure of the efficacy of cyclosporin A-based immunosuppression. *Clin Chem* 48(12): 2225-2231.
 75. Sommerer C, Konstandin M, Dengler T, Schmidt J, Meuer S, et al. (2006) Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. *Transplantation* 82(10): 1280-1285.